DiaMedica Therapeutics Inc’s filing revealed that its 10% Owner STAHLBERG JAN acquired Company’s shares for reported $2.03 million on Aug 25 ’25. In the deal valued at $6.00 per share,338,265 shares were bought. As a result of this transaction, STAHLBERG JAN now holds 7,654,045 shares worth roughly $52.2 million.
Then, STAHLBERG JAN bought 293,601 shares, generating $1,734,918 in total proceeds. Upon buying the shares at $5.91, the 10% Owner now owns 7,058,066 shares.
Before that, STAHLBERG JAN bought 70,414 shares. DiaMedica Therapeutics Inc shares valued at $421,921 were divested by the 10% Owner at a price of $5.99 per share. As a result of the transaction, STAHLBERG JAN now holds 7,128,480 shares, worth roughly $48.62 million.
H.C. Wainwright initiated its DiaMedica Therapeutics Inc [DMAC] rating to a Buy in a research note published on October 07, 2024; the price target was $7. Oppenheimer also remained covering DMAC and has increased its forecast on June 22, 2023 with a “an Outperform” recommendation from previously “Perform” rating. Oppenheimer started covering the stock on April 09, 2021. It rated DMAC as “an Outperform”.
Price Performance Review of DMAC
On Friday, DiaMedica Therapeutics Inc [NASDAQ:DMAC] saw its stock jump 0.89% to $6.82. Over the last five days, the stock has lost -3.81%. DiaMedica Therapeutics Inc shares have risen nearly 56.78% since the year began. Nevertheless, the stocks have risen 25.60% over the past one year.
How much short interest is there in DiaMedica Therapeutics Inc?
A steep rise in short interest was recorded in DiaMedica Therapeutics Inc stocks on 2025-08-29, growing by 0.75 million shares to a total of 4.03 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 3.28 million shares. There was a rise of 18.54%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 17, 2021 when ROTH Capital began covering the stock and recommended ‘”a Buy”‘ rating along with a $38 price target.
